Citius Oncology, Inc. Common Stock
Symbol: CTOR (NASDAQ)
2.00
▼ (-1.53%) -0.031
Company Description:
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Key Stats
- Today's Open: $2.05
- Today's High: $2.075
- Today's Low: $1.945
- Today's Volume: 164.96K
- Yesterday Close: $2.03
- Yesterday High: $2.1
- Yesterday Low: $1.91
- Yesterday Volume: 289.86K
- Last Min Volume: 0
- Last Min High: $1.999
- Last Min Low: $1.996
- Last Min VWAP: $0
Company Profile
- Name: Citius Oncology, Inc. Common Stock
- Website: https://www.citiusonc.com
- Listed Date: 2024-08-13
- Location: CRANFORD, NJ
- Market Status: Active
- CIK Number: 0001851484
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $169.53M
- Round Lot: 100
- Outstanding Shares: 83.51M
- Asset Type: CS
RECENT FILINGS FOR CTOR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-26 | DEF 14A | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 4 | View |
| 2025-09-19 | S-8 | View |
| 2025-09-19 | 8-K | View |
| 2025-09-12 | SCHEDULE 13D/A | View |
| 2025-09-10 | 424B3 | View |
| 2025-09-10 | 8-K | View |
| 2025-09-10 | 424B5 | View |
| 2025-09-04 | EFFECT | View |
| 2025-09-02 | S-3 | View |
| 2025-08-20 | DRS | View |
Latest News on CTOR